Otsuka Holdings (4578) · InitiativeAchieved
Acquisition of an antibody drug discovery platform through the acquisition of Visterra
First written in FY2018-Q2. 1 of 2 entries say "Achieved", first in FY2018-Q3. Latest entry: FY2018-Q3.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Acquisition of an antibody drug discovery platform through the acquisition of VisterraA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2018-Q3AchievedAnnual report
「On 11 July 2018, Otsuka Pharmaceutical Co., Ltd. agreed to make Visterra, Inc., a US company engaged in pharmaceutical research and development, a wholly owned subsidiary through an acquisition vehicle established by Otsuka America, Inc., a consolidated subsidiary of the company. The acquisition was completed on 31 August.」
The acquisition of Visterra, for which the agreement had been disclosed in the previous quarter, was completed on 31 August 2018. The company acquired an antibody drug discovery platform including the Hierotope® platform and VIS649. - FY2018-Q2First statedAnnual report
「Through this acquisition, Otsuka Pharmaceutical will advance further drug development by acquiring a new antibody drug discovery platform in addition to its existing small-molecule drug discovery capabilities.」
On 11 July 2018, the company entered into an agreement to make US-based Visterra, Inc. a wholly owned subsidiary for cash consideration of US$430 million. The acquisition was scheduled to close during the third quarter of 2018. Visterra has the Hierotope® platform, which designs antibody structures computationally, and planned to begin clinical trials during the year for VIS649, a treatment for IgA nephropathy.